Price movement over the last 24 hours
Align Technology, Inc. vs Invesco Preferred ETF — how do they compare? Align Technology, Inc. trades at $179.45 (market cap $12.86B), while Invesco Preferred ETF trades at $10.87. The key difference: Align Technology, Inc. is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| ALGN | PGX | |
|---|---|---|
Market Cap | $12.86B | — |
Sector | Health | — |
52-Week High | $207.19 | $11.87 |
52-Week Low | $124.88 | $10.82 |
Enterprise Value | $11.92B | — |
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
PGX trades at $10.85, down slightly by 0.09% in the last session. The technical outlook is bearish, with moving averages signaling a downtrend and oscillators neutral. The company recently announced the sale of its Golden Sidewalk Project to Kenorland Exploration Ltd. on June 18, 2026, as per GlobeNewsWire, which may impact future asset base and revenue streams.
The outlook remains cautious due to bearish technical signals and negative media sentiment highlighting poor returns and limited downside protection. Risks include execution of asset sales and market volatility. Analyst sentiment appears negative, with institutional selling noted in recent filings.
Trailing returns across standard periods
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →